# Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell

> **NCT03019055** · PHASE1 · COMPLETED · sponsor: **Medical College of Wisconsin** · enrollment: 26 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin
- Lymphoma, B-Cell
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **BIOLOGICAL:** CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)
- **BIOLOGICAL:** CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg)
- **BIOLOGICAL:** CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg)
- **BIOLOGICAL:** CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)

## Key facts

- **NCT ID:** NCT03019055
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-16
- **Primary completion:** 2019-10-01
- **Final completion:** 2021-08-24
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2023-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03019055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03019055, "Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03019055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*